Drug for Relieving MS Symptoms Birmingham AL

During the three-year study, the patients were assessed every three months. Those who took the steroid/interferon drug combination had 38 percent fewer relapses (episodes when the disease is active) than those who took the placebo and interferon, the study found.

Local Companies

Catholic Family Services
205-324-6561
1515 12th Ave S
Birmingham, AL
Triumph Services, Inc.
205-581-1000
2216 10th Ct. S.
Birmingham, AL
Canterbury Counseling Center
205-879-0202
350 Overbrook RD
Birmingham, AL
Alabama Counseling LLC
205-423-0083
4 Office Park Cir
Birmingham, AL
Dickinson Daphne F M Ed NCC LPC
205-822-7774
3253 Lorna Rd
Birmingham, AL
Stress Control Counseling Service
205-933-9191
1425 Richard Arrington Jr Blvd S
Birmingham, AL
Consumer Credit Counseling
205-251-1572
1401 20th St S
Birmingham, AL
Alabama Board of Examiners In Counseling
205-458-8716
950 22nd St N
Birmingham, AL
Stanley Haluska CCH
205-414-9388
13 Office Park Cir
Birmingham, AL
Joan Leary Counseling, LLC
205-529-5565
402 Office Park Drive, Suite 250
Birmingham, AL

Using a steroid drug in combination with a multiple sclerosis (MS) drug may give patients more relief from symptoms than using the MS drug alone, suggests a new study.

In the study, which included 341 people with relapsing-remitting MS, some patients were randomly selected to receive the steroid drug methylprednisolone in three doses over three days once a month, in addition to regular treatment with the MS drug interferon beta-1a. Others received the interferon drug and a placebo.

During the three-year study, the patients were assessed every three months. Those who took the steroid/interferon drug combination had 38 percent fewer relapses (episodes when the disease is active) than those who took the placebo and interferon, the study found. The patients in the steroid/interferon group also showed slight improvement on a test of MS disability, while those in the placebo/interferon group showed a slight decline.

The Biogen Idec-supported study also found that MS-related brain lesions stayed the same size or shrank in the steroid/interferon group but grew larger in the placebo/interferon group. The findings were presented this week at the annual meeting of the American Academy of Neurology, in Seattle.

"These results indicate that these two drugs may have a synergy when taken together and provide a more beneficial effect on the disease activity," study author Dr. Mads Ravnborg, of the Danish Multiple Sclerosis Research Center at Copenhagen University Hospital in Denmark, said in an American Academy of Neurology news release. "This is a promising finding, as the benefit from interferon is only moderate, and not everyone responds fully to the treatment, so anything we can do to boost those results is positive."

More information

The National Multiple Sclerosis Society has more about MS treatments.

SOURCE: American Academy of Neurology, news release, April 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Featured Local Company

Stress Control Counseling Service

205-933-9191
1425 Richard Arrington Jr Blvd S
Birmingham, AL